Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Arcadia Biosciences (RKDA) EBITDA Margin (2016 - 2025)

Historic EBITDA Margin for Arcadia Biosciences (RKDA) over the last 12 years, with Q3 2025 value amounting to 88.48%.

  • Arcadia Biosciences' EBITDA Margin rose 260300.0% to 88.48% in Q3 2025 from the same period last year, while for Sep 2025 it was 65.76%, marking a year-over-year decrease of 101800.0%. This contributed to the annual value of 72.31% for FY2024, which is 646900.0% up from last year.
  • As of Q3 2025, Arcadia Biosciences' EBITDA Margin stood at 88.48%, which was up 260300.0% from 34.43% recorded in Q2 2025.
  • In the past 5 years, Arcadia Biosciences' EBITDA Margin registered a high of 248.55% during Q1 2021, and its lowest value of 375.3% during Q2 2021.
  • For the 5-year period, Arcadia Biosciences' EBITDA Margin averaged around 88.69%, with its median value being 107.63% (2023).
  • The largest annual percentage gain for Arcadia Biosciences' EBITDA Margin in the last 5 years was 30727400bps (2021), contrasted with its biggest fall of -5682800bps (2021).
  • Arcadia Biosciences' EBITDA Margin (Quarter) stood at 215.3% in 2021, then surged by 134bps to 73.02% in 2022, then crashed by -310bps to 153.54% in 2023, then decreased by -22bps to 187.42% in 2024, then surged by 53bps to 88.48% in 2025.
  • Its EBITDA Margin was 88.48% in Q3 2025, compared to 34.43% in Q2 2025 and 44.17% in Q1 2025.